NCCN 10th Annual Congress: Hematologic Malignancies™

San Francisco, CA US
October 16, 2015 to October 17, 2015

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.




Target Audience

This congress is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Patient Case Studies & Panel Discussion (Double-hit Lymphoma, T-cell Lymphoma, Mantle Cell Lymphoma)

  • Discuss the molecular and clinical features of double-hit lymphoma, T-cell lymphoma and mantle cell lymphoma
  • Develop an evidence-based approach for the evaluation and treatment of the 3 subtypes of NHL

Optimizing Small Molecular Inhibitor Therapy for Chronic Lymphocytic Leukemia

  • Understand the special considerations associated with the use of small molecule inhibitors

Evolving Therapies for Follicular Lymphoma

  • Discuss the mechanism action, safety and efficacy of novel targeted therapies in the management of patients with follicular lymphoma

Management of HIV-associated Non-Hodgkin’s Lymphomas

  • Discuss the treatment options for patients with HIV-associated DLBCL and BL

Evolving Targeted Management of Acute Myeloid Leukemia

  • Identify the latest advances and current therapeutic strategies to optimize outcomes of patients with AML

Patient Case Studies & Panel Discussion (Myeloproliferative Disorders, Elderly Myelofibrosis, Hemophagocytic Syndromes)

  • Explain the challenges of diagnosing and subsequently treating the more rare clinical presentations in patients with myeloproliferative neoplasms, elderly myelofibrosis, and  hemophagocytic lymphohistiocytosis

Management of Myelodysplastic Syndromes

  • Summarize the current and developing complementary diagnostic assays and molecular analyses and how these tests can be used to advance the classification and prognostication of MDS

Management of Acute Lymphoblastic Leukemia

  • Elaborate on the studies that support the use of immunotherapies and expound on the unique complications of this class of drug

Survivorship Issues: Late Effects of Curative Therapy in Lymphoma Survivors

  • Identify the risk factors associated with the development of long-term complications for survivors of HL and NHL

Patient Case Studies & Panel Discussion (Amyloidosis, POEMS Syndrome, Plasmacytoma)

  • Understand clinical features, diagnosis, and treatment of plasma cell disorders such as amyloidosis, POEMS syndrome and plasmacytoma

Advances in Waldenström's Macroglobulinemia

  • Discuss the diagnosis, workup,  and currently available agents for management of Waldenström’s Macroglobulinemia

Management of Multiple Myeloma

  • Explain current treatment strategies and the future directions in management of multiple myeloma

Bone Health in Patients with Multiple Myeloma

  • Outline strategies for management of bone disease in multiple myeloma

Diagnosis and Treatment of Castleman Disease

  • Identify the clinical and pathological features associated with the different subtypes of Castleman disease

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma

  • Describe the Deauville response criteria and data from clinical trials evaluating risk-adapted PET-guided treatment approach for patients with advanced stage CHL

Targeted Therapies for Relapsed or Refractory Classical Hodgkin Lymphoma

  • Review the clinical evidence from ongoing trials evaluating novel treatment options and the potential role of new agents in the treatment algorithm for patients with relapsed or refractory CHL
Additional information

This activity is supported by an independent educational grant from Incyte Corporation.

This activity is supported by educational funding provided by Amgen.

This activity is supported by educational grants from:

  • AbbVie Inc.
  • Actelion Pharmaceuticals US, Inc.
  • Astellas Scientific and Medical Affairs, Inc.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genentech
  • Gilead Sciences, Inc.
  • Novartis Pharmaceuticals Corporation
  • Pharmacyclics LLC, An AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer
  • Seattle Genetics
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Oncology


This list of supporters was last updated on October 2, 2015.

Course summary
Available credit: 
  • 9.00 Participation
  • 8.24 Nurse
  • 9.00 Pharmacist
  • 9.00 Physician
Course opens: 
Course expires: 
Event starts: 
10/16/2015 - 4:30pm EDT
Event ends: 
10/17/2015 - 5:00pm EDT
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
United States

This congress is approved for AMA PRA Category 1 Credit™ and is also certified for nurses and pharmacists. Learn more.

Available Credit

  • 9.00 Participation
  • 8.24 Nurse
  • 9.00 Pharmacist
  • 9.00 Physician


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing